OncoMatch/Clinical Trials/NCT07663864
Luspatercept for CIA in AML
Official title: Efficacy and Safety of Luspatercept in Treating Chemotherapy-inducing Anemia in Acute Myeloid Leukemia: a Multicenter, Prospective, Single-arm Study
Is NCT07663864 recruiting? Yes, currently enrolling (Oct 2026). This Phase 1/2 trial studies Luspatercept Injectable Product for chemotherapy-inducing anemia.
Treatment: Luspatercept Injectable Product — This study aims to explore the feasibility, safety, and preliminary efficacy of rotegcipipone in the treatment of chemotherapy-inducing anemia in AML with a multicenter, prospective, single-arm trial, providing clinical evidence for subsequent clinical development.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: HDAC consolidation therapy
Received 1-3 cycles of HDAC consolidation therapy
Lab requirements
Blood counts
HGB 60-90 G/L
Kidney function
creatinine clearance < 30 ml/min [excluded]
Liver function
ALTd > 5 times normal, bilirubin > 3 times normal [excluded]
Cardiac function
Heart function < grade 2 [excluded]
HGB 60-90 G/L; Heart function < grade 2 [excluded]; creatinine clearance < 30 ml/min [excluded]; ALTd > 5 times normal, bilirubin > 3 times normal [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07663864 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received HDAC consolidation therapy.
Is there an age limit?
Yes. Patients must be 60 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages